White paper · Medical dermatology · Q4 2026
Demand, capacity and the case for a better-connected route to clinical decisions in UK skin care. Published by RADAR Skin Health; evidence reviewed to October 2026.
- People in England and Wales see a GP about a skin condition each year
- 1 in 4
- Source 1
- First attendances in adult dermatology in England
- 1.56m
- 2025–26 · Source 18
- Dermatology treatment pathways waiting in England
- 423,217
- August 2026 · Source 3
- Consultant dermatologists on the UK Specialist Register
- 1,340
- 2024 · Source 4
Executive summary: a pathway problem as well as a capacity problem
Skin disease is one of the largest and most varied areas of clinical demand in the UK. Around half the population experiences a skin condition in a typical year, and one in four people in England and Wales consults a GP about one. [1, 2] Most are managed in primary care, yet hospitals in England still recorded 4.25 million dermatology outpatient attendances in 2025–26, including 1.56 million first attendances in adult dermatology alone. [18] Those presentations arrive at a specialty whose waiting list has more than doubled since 2020 and whose consultant workforce is already below the minimum its professional body has modelled. [3, 4, 15]
This paper argues that adding appointments alone cannot close that gap. The pressure is created as much by how cases move through the pathway as by how many there are. Five findings run through the evidence:
- Demand is broad and accelerating. The category spans transient rashes, chronic inflammatory disease, benign lesions and potentially malignant change. Melanoma has reached a record level, and urgent referrals for suspected skin cancer in England rose by 57% between October 2021 and October 2025. Greater awareness brings more low-risk cases forward for reassurance. [6, 19]
- The specialist workforce cannot absorb growth through appointments. The 2024 British Association of Dermatologists (BAD) census found a material consultant shortfall, high vacancy levels, more part-time working and an ageing workforce. NHS and private provision draw heavily on the same clinicians. [4, 5]
- The pathway itself creates avoidable work. Incomplete histories, inconsistent photography, uncertain thresholds and fragmented records lead to repeat consultations, returned referrals and duplicated specialist assessment. [1, 2]
- Remote, image-enabled pathways can improve flow, but results depend on design. Published services show faster review and fewer face-to-face appointments for some groups of patients. National guidance also warns that poor images, weak integration or unfunded specialist review can move work rather than remove it. [1, 7, 8, 11, 12]
- The opportunity is a managed clinical pathway. The unit of value is a safe, documented clinical decision and the correct onward route, rather than the number of images collected, cases opened or remote reviews completed.
Scope. This paper examines medical dermatology rather than cosmetic skin care. It draws on national guidance, official waiting-list, outpatient and referral data, workforce research and published service evaluations, and does not assess or endorse any individual technology. Evidence is UK-wide, with England-specific operational statistics identified as such, and was reviewed to October 2026.
01 · Scale: a large category without a single market
The story starts with the size and shape of demand. Medical skin care is often described as one market, but patient need moves through several overlapping systems. Consumer skin care, GP-led treatment, specialist medical dermatology, skin-cancer diagnostics and procedural services each have different entry points, economics and clinical risks. Public, insured, self-pay and mixed NHS-private activity are measured in different ways, so a single revenue estimate would create false precision. What the layers share is a decision that has to be made at each one.
| Category layer | Typical need | The decision to be made |
|---|---|---|
| Self-care and pharmacy | Minor, familiar or recurrent symptoms | Can the person manage safely without a clinician? |
| Primary and private general practice | First assessment, initial treatment and safety-netting | Can this be managed in primary care, or is specialist input needed? |
| Specialist advice and medical dermatology | Diagnostic uncertainty, treatment escalation and complex disease | Is advice sufficient, or is a specialist appointment required? |
| Cancer and procedural pathways | Suspicious lesions, biopsy, excision and treatment | How urgent is the case, and what is the correct definitive pathway? [13] |
Activity in numbers: dermatology in England, 2025–26
- Dermatology outpatient attendances
- 4.25m
- Adult and paediatric · Source 18
- First attendances in adult dermatology
- 1.56m
- Source 18
- Share of all first outpatient attendances
- 4.0%
- Compared with 3.5% of all attendances · Source 18
- Follow-ups per first attendance
- 1.62
- Compared with 2.02 across all specialties · Source 18
Dermatology is a front-door specialty. It accounts for a larger share of first outpatient attendances than of total hospital activity, and sees fewer follow-ups per first attendance than the average, so its pressure arrives largely as new demand rather than as a long tail of review. Primary care is under similar strain: 387.8 million appointments were recorded in GP practice systems in England in the 12 months to August 2026, 4.6% more than in the previous 12 months. Those data do not record why people attend, so they describe the setting skin demand lands in rather than its size. [20]
Five forces are expanding assessment demand
- High underlying prevalence. Around half the UK population experiences a skin condition in a 12-month period. [2]
- Cancer incidence. 20,980 people in the UK were diagnosed with melanoma in 2022, the first year above 20,000. Cancer Research UK projects about 26,500 cases a year by 2040. [6, 17]
- Age and complexity. An older population increases lesion burden, multimorbidity and the need to distinguish benign change from malignancy.
- Awareness and reassurance. Greater awareness supports earlier presentation, but also brings more low-risk cases into clinical pathways. Urgent referrals for specialist skin assessment rose by 170% over ten years, and urgent suspected skin cancer referrals by 57% in the four years to October 2025. [15, 19]
- Access expectations. Patients increasingly expect rapid, convenient answers and visibility of the next step, whether their care is NHS, insured or self-pay. For many, the answer they need is reassurance, and they need it quickly.
Monthly rise: 57% in four years. Source: West Midlands Cancer Alliance, Skin cancer best practice implementation handbook, April 2026. [19]
Annual rise: about 12–16% in two years. The 2025–26 total is RADAR’s estimate based on monthly referral levels to October 2025; it is not a published annual count. The source recommends replacing it when the annual figure becomes available. [19]
02 · Capacity: the constraint is structural
That rising demand meets a specialty with little room to expand. At the end of August 2026, 423,217 dermatology treatment pathways were waiting in England, 5.9% of the entire NHS waiting list of 7,189,213 pathways. Only 69.0% had waited less than 18 weeks. That is up from 64.2% a year earlier, but still far short of the 92% constitutional standard, which the Government has committed to restoring by March 2029. [3, 16] Some 5,256 pathways had been waiting for more than a year. These statistics count pathways, not unique people. Because reporting coverage has changed over time, the percentages are a more reliable guide to the trend than the count. [3] In January 2025 the BAD reported that dermatology waiting lists stood 118% above their July 2020 level. [15]
- Within 18 weeks69%
- Beyond 18 weeks31%
423,217 waiting treatment pathways. Standard: 92% within 18 weeks. Source: NHS Wait Helper, August 2026. [3]
Modelled shortfall: 89.5 whole-time-equivalent consultants. Source: BAD Workforce Census 2023–24. The minimum workforce is the BAD model, not a government target. [4]
The workforce cannot be treated as two separate pools
The BAD identified 1,340 consultant dermatologists on the UK Specialist Register in 2024. Its census found 75 members working only in private practice, and among 720 NHS consultant respondents, 323 also undertook private work: 99 of the full-time consultants and 224 of the part-time consultants. These are survey results rather than a complete census, but they show substantial overlap between NHS and private capacity. [4]
The gap is set to widen. BAD modelling estimated an England shortfall of 89.5 whole-time-equivalent (WTE) consultants in 2023. Hospitals responding to its survey reported 96.8 WTE vacancies across the UK, and its membership analysis projected about 27.2 WTE retirements a year over the following five years, before accounting for consultants already working beyond 65. [4, 5] Official data on the shortfall is limited: asked about it in Parliament in March 2026, the Government replied:
03 · Pathway friction: where the pathway becomes blocked
If capacity cannot grow quickly, the next question is how it is being used. Volume explains only part of the pressure. Each hand-off can add waiting, uncertainty and rework: the same patient may describe the problem more than once, have images taken more than once, and wait for more than one clinician to decide what should happen next.
| Stage | Typical friction | System consequence | The better-pathway question |
|---|---|---|---|
| Patient entry | Uncertainty about whether a change needs clinical assessment | Anxiety, delayed presentation or an avoidable consultation | Can the patient reach a safe first decision quickly? |
| Initial assessment | Short appointments, variable experience and inconsistent images | Repeat consultations or precautionary referral | Is there enough information to make or support a decision? |
| Referral | Incomplete history, variable thresholds and unclear service criteria | Returned referrals, duplicated work or inaccurate priority | Can the receiving clinician act without reconstructing the case? |
| Specialist review | Scarce clinical time used on incomplete or low-risk cases | Slower review of complex and higher-risk patients | Is specialist expertise being used where it changes the outcome? |
| Follow-up | Fragmented records, unclear ownership and weak safety-netting | Missed follow-up, repeated contact and unresolved anxiety | Is the outcome recorded, communicated and tracked? |
The cost of that friction is felt most sharply on the urgent pathway. There were 715,803 urgent suspected skin cancer referrals in England in 2023–24, while adult dermatology recorded 1.56 million first attendances in 2025–26. These figures demonstrate scale, but refer to different periods and measure different activity; they cannot establish what proportion of all dermatology referrals were urgent skin cancer referrals. [18, 19]
NHS England data cited by the BAD show that only 6% of urgent referrals for suspected skin cancer led to a confirmed cancer diagnosis. [15, 16] For the other 94%, cancer was not confirmed; those patients may still need reassurance or other care after a period of waiting. Applying that rate to an illustrative 800,000 urgent referrals a year gives around 48,000 referrals resulting in confirmed cancer and 752,000 without confirmed cancer. These are illustrative referral counts, not measured annual totals or counts of unique people.
- Confirmed skin cancer6%
- No confirmed skin cancer94%
Illustration: applying the 6% rate to an estimated 800,000 referrals gives about 48,000 with confirmed skin cancer and 752,000 without. Source: NHS England data cited by BAD, July 2025; RADAR’s 2025–26 annual referral estimate. [15, 19]
The output that matters is a decision, not an appointment
A skin presentation does not automatically need a face-to-face GP or dermatologist appointment. It needs a safe determination among a limited number of routes: self-care or advice, primary-care treatment, specialist advice, routine specialist review, urgent cancer assessment or a procedural pathway. [2, 13] An appointment is one way of reaching that decision, not the unit of value in itself. Four questions sit at the heart of every case:
Does this need clinical review?
Establish whether a clinical assessment is needed.
Can primary care manage it safely?
Determine whether primary-care treatment and safety-netting are appropriate.
Would specialist advice change the plan?
Use specialist expertise where it supports the next decision.
Does it require urgent review or a procedure?
Identify the correct urgency and definitive pathway.
04 · Decision quality: better information is the pathway infrastructure
Answering those four questions well depends on what the decision-maker can see. Remote review succeeds or fails on the quality of the case presented. National guidance consistently emphasises structured clinical information, usable images, clear responsibility and communication of the outcome. The 2024 BAD standards specify core history and image requirements, including location, close-up and profile images where appropriate, and state that dermoscopy is essential for virtual diagnosis in urgent suspected skin-cancer pathways. [7, 8] Six components make up a decision-ready case:
Structured history
Symptoms, duration, change, treatment, relevant history and risk factors are captured once, in a consistent form.
Clinically usable images
Images show location and detail, meet an agreed standard and can be viewed securely by the decision-maker.
Named clinical responsibility
The patient and referrer know who is responsible for the decision, communication and onward action.
A defined outcome set
Advice, treatment, monitoring, referral, urgency and safety-netting are recorded in standard terms.
Record integration
The original information, images, decision and next step remain visible in the patient record.
Closed-loop follow-up
Patients receive the outcome, understand what to do next and can re-enter the pathway if the condition changes.
Image quality is not a technical detail
Good images can reduce unnecessary double handling, but poor images can turn a remote interaction into an extra step before a face-to-face appointment. NHS England therefore recommends that high-quality images, including dermoscopic images of lesions where appropriate, accompany specialist advice requests. Patient-supplied images may be useful, but they are not always sufficient for specialist review. [2, 7]
Quality also has an equity dimension. Digital access, language, disability, confidence with technology, lesion location and the representation of different skin tones can all affect whether a remote route works. Pathway redesign must keep practical alternatives in place and monitor who is excluded, delayed or returned to face-to-face care. [9]
05 · Evidence: remote pathways can release capacity, but the model matters
Where those foundations are in place, the evidence is encouraging. Outcomes still vary with patient selection, image capture, specialist integration and the measure used, so case studies should not be read as universal conversion rates.
| Evidence | Finding | What it suggests | Important qualification |
|---|---|---|---|
| National pathway guidance | NHS England advocates pre-referral specialist advice followed by triage as the main route into specialist dermatology, except for urgent suspected skin cancer. [2, 8] | Supports redesign around earlier decisions and closer generalist–specialist working. | Requires agreed response times, interoperability and clear communication. |
| Royal Cornwall community imaging | Among 438 patients, 49.8% avoided a face-to-face assessment. Clinician review averaged about 3 minutes, against 20 for a traditional appointment. [11] | Standardised imaging and consultant tele-triage can change how patients are routed. | A single service; results depend on pathway design and case mix. |
| Large urban store-and-forward service | Across 8,352 patients, 56.8% were returned to their GP, 19.6% went directly to surgery and 23.6% had face-to-face specialist review. [12] | Remote review creates several onward routes, not simply discharge or appointment. | Medical photographers produced unusually high image quality; not directly transferable to patient-captured models. |
| GIRFT national review | Wide variation in integration, and conflicting evidence on outcomes, cost and referral reduction. [1] | A necessary counterweight to promotional case studies. | Long-term safety, referral-rate and health-economic evaluation is needed. |
- Returned to GP with advice or no further treatment56.8%
- Direct to surgery19.6%
- Face-to-face dermatologist review23.6%
8,352 patients. Source: Palamaras et al., Journal of Visual Communication in Medicine, 2022. Observational service data, not a controlled comparison. [12]
Technology can also move the bottleneck
A remote front door may reduce booked appointments yet increase total contacts, create image-taking work, add specialist review outside job plans, or generate demand from patients who would otherwise have self-cared. GIRFT therefore recommends measuring referral rates, safety, time to correct diagnosis, treatment effectiveness, patient experience, equity and the overall health-economic effect. [1] The same caution applies to artificial intelligence: NICE’s 2025 assessment of AI technologies for triaging lesions on the urgent suspected skin-cancer pathway underlines how much depends on evidence and implementation. [10]
06 · Pathway design: eight principles for a better skin assessment pathway
The evidence points to a consistent set of design choices. Together they shift the focus from the channel to the decision.
Start with the clinical decision
Choose the care channel after assessing what information and expertise the case requires.
Capture once and reuse
A structured history and image set should support advice, referral, triage and follow-up without re-keying.
Apply explicit inclusion criteria
Define which conditions, body sites, patient groups and urgency levels are suitable for remote review.
Protect specialist capacity
Allocate funded, job-planned review time and route cases to the lowest appropriate level of expertise. [14]
Keep clinicians accountable
Decision support may organise information, but clinical responsibility and escalation rules must remain clear.
Integrate the outcome
The decision, reasoning, images and next step should form part of the longitudinal patient record.
Design for equity and choice
Provide supported image capture and non-digital alternatives, and test performance across skin tones and patient groups. [9]
Measure net pathway impact
Judge the model on resolved episodes, safety, total activity, patient experience and cost across the pathway. [1]
Capture
History and images
Assess
Completeness and risk
Decide
Clinical outcome
Route
Right service and urgency
Track
Communication and safety-netting
Learn
Audit and improve
07 · Private care: what this means for private GPs and dermatologists
Private care has greater freedom to redesign access and service models, but it works within the same clinical constraints and, as Section 2 showed, largely the same consultant workforce. The opportunity is to build a more reliable interface between patients, generalists and specialists, beyond offering a remote consultation.
| Issue | For private GPs | For dermatologists |
|---|---|---|
| Access | Offer a rapid route for skin concerns without automatically consuming a standard appointment. | Extend specialist input beyond booked clinics where governance, time and payment are explicit. |
| Decision quality | Use structured information to manage appropriate cases and refer with greater precision. | Receive cases with usable history and images, reducing reconstruction and rework. |
| Patient proposition | Provide faster certainty, continuity and a visible next step. | Prioritise complex, procedural and higher-risk patients while supporting lower-risk cases remotely. |
| Economics | Measure cost and revenue per resolved episode, including staff time and onward activity. | Value advice and triage as clinical work, not as an unpaid prelude to an appointment. |
| Governance | Define responsibility, escalation, consent, records and safety-netting before launch. | Set inclusion criteria, image standards, turnaround times and links to local urgent pathways. [7, 13] |
| Relationship | Build an ongoing GP–specialist interface rather than a one-way referral transaction. | Use advice as a route to education and better future referrals, without de-skilling primary care. |
Avoiding a false win
A practice may appear to improve access while transferring work elsewhere. Digital intake can reduce reception calls but increase clinician review; remote review can reduce booked appointments but increase imaging activity; specialist advice can avoid a referral but create unfunded consultant work. A credible model counts the whole episode, including patient effort, administrative work, repeat contact and downstream care.
08 · Evaluation: a scorecard for new service models
Avoiding a false win requires measuring the right things. Providers should evaluate a pathway before evaluating its technology. These measures distinguish genuine service improvement from channel substitution. [1, 7]
| Evaluation domain | Questions and measures |
|---|---|
| Clinical safety | Diagnostic concordance where measurable; urgent escalation; adverse incidents; missed or delayed malignancy; quality of safety-netting. |
| Decision quality | Proportion of cases with a documented outcome; appropriateness of onward route; returned or rejected referrals; repeat assessment. |
| Pathway time | Submission to clinical decision; decision to treatment; time to communicate the outcome; urgent-pathway compliance. [13] |
| Capacity effect | Face-to-face appointments avoided; specialist and GP review time; image-capture work; net change in total contacts. |
| Integration | Proportion of cases recorded without re-keying; access to original images and history; completion of onward action. |
| Patient experience | Understanding of the outcome; reassurance; convenience; choice; ease of re-access; travel and time saved. |
| Equity | Access and outcomes by age, ethnicity, skin tone, disability, language, deprivation and digital confidence. [9] |
| Economics | Cost per resolved episode; revenue and margin by pathway; avoided duplication; effect on higher-value clinical capacity. |
| Workforce sustainability | Review work included in job plans; training and supervision; effect on primary-care confidence and specialist workload. [5, 14] |
| Evidence maturity | Sample size; comparator; case mix; follow-up period; independent evaluation; transparent limitations. |
09 · Conclusions: skin care needs a better front end
The UK skin pathway carries a large and growing volume of clinically diverse demand into a constrained workforce. The result is not simply a long specialist waiting list. It is repeated assessment, variable information, uncertain routing and too much scarce clinical time spent reconstructing or reprioritising cases. The way forward follows from the evidence:
- The problem begins before referral. Patients and GPs need faster access to a reliable first decision, not just faster access to the same appointment pathway.
- Information quality is a capacity intervention. A structured history and clinically usable images can reduce rework and allow earlier, more confident routing.
- Specialist advice must be designed as a service. It needs explicit capacity, response times, governance, integration and payment, rather than relying on discretionary clinician effort. [8, 14]
- Remote care is valuable when it shortens the whole pathway. Avoiding one appointment is not success if the patient needs repeated contact or the work simply moves to another clinician.
- Evidence should follow the episode. The strongest evaluation links early decisions to subsequent referrals, treatment, safety, patient experience and total cost.
Questions the sector still needs to answer
- What proportion of skin presentations can be safely resolved without a conventional appointment, by condition and risk group?
- Which information and image standards most improve decision quality without creating excessive work for patients or practices?
- How should clinical responsibility and payment be allocated when care crosses patient, GP and dermatologist interfaces?
- Do remote pathways reduce total activity and time to treatment, or merely redistribute contacts?
- How do outcomes vary across skin tones, age groups, lesion locations, digital ability and socioeconomic groups?
- What is the cost per safely resolved episode, compared with existing private and NHS pathways?
Contribute to the UK Skin Pathway Benchmark
We are inviting private GPs and dermatologists to share how skin presentations are currently assessed, managed and referred. It takes two minutes. Contributors will receive the aggregated findings and can compare their pathway with the wider market.
Take the 2-minute questionnaire.
Method and sources: scope and limitations
This white paper was prepared and published by RADAR Skin Health in Q4 2026. It is a secondary-research discussion paper. It combines UK and England-specific evidence published by NHS England, the Department of Health and Social Care, the British Association of Dermatologists, Getting It Right First Time, NICE, Cancer Research UK and peer-reviewed or provider-reported service evaluations.
It does not estimate a single commercial market value, because comparable public and private activity and revenue data are not available across the full pathway. Figures refer to different periods, populations and definitions: waiting-list statistics count pathways rather than unique patients and may exclude non-reporting providers, and workforce figures combine register data, published whole-time-equivalent statistics and survey results.
Outpatient figures are from Hospital Episode Statistics for 2025–26; they count attended appointments rather than unique patients, include NHS-commissioned activity in the independent sector, and record first attendances, which are not the same as referrals. Urgent referral and outpatient figures are for England only, and the 2025–26 urgent referral total is an estimate. GP appointment data do not record the reason for an appointment, so they describe overall primary-care activity rather than skin-specific demand.
Service evaluations illustrate achievable pathway effects; they do not predict outcomes for another service. Quotations are reproduced from the published sources listed. This paper does not provide clinical advice and does not evaluate a named product. Any pathway change requires local clinical governance, information-governance review, an equality impact assessment and appropriate evaluation.
Web edition notes. The source’s waiting-list and outpatient labels have been aligned with its own methodology: these are waiting pathways and first attendances, not unique people or new referrals. The cross-period referral/attendance comparison is presented as context rather than a calculated share. The 8,352-patient study attribution has been corrected to Palamaras and colleagues in the Journal of Visual Communication in Medicine. The source’s historical estimates and evidence dates are retained.
References
- Getting It Right First Time. Dermatology: GIRFT Programme National Specialty Report. August 2021.
- NHS England. Referral optimisation for people with skin conditions. 27 September 2022.
- NHS Wait Helper. Dermatology waiting times, England: end of August 2026. Accessed 15 October 2026.
- British Association of Dermatologists. BAD Workforce Census Report 2023–24. September 2024.
- British Association of Dermatologists. BAD Workforce Strategy. September 2024.
- Cancer Research UK. Melanoma skin cancer cases hit a record high in the UK. 22 May 2026.
- British Association of Dermatologists. Service guidance and standards for teledermatology. 2024.
- NHS England. A teledermatology roadmap: implementing safe and effective teledermatology triage pathways and processes. June 2023.
- NHS England. Ensuring equity of access to care when redesigning dermatology pathways. 2022.
- NICE. Artificial intelligence technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway (HTG746): committee discussion. 2025.
- Royal Cornwall Hospitals NHS Trust. Award-winning tele-triage pathway helps to maintain first-class dermatology patient care. 7 February 2025.
- Palamaras I et al. Clinical outcomes and operational impact of a medical photography based teledermatology service with over 8,000 patients in the UK. Journal of Visual Communication in Medicine. 2022;45(1):6–17. DOI: 10.1080/17453054.2021.2004883.
For a shorter overview, read the skin pathway bulletin. See the eight-week GP pilot, or request a demonstration to discuss the workflow.